Page 322 - AIDSBK23C
P. 322
Page 322
299 Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban
clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med.
1999;131:81-87.
300 Eron JJ, Vernazza PL, Johnston DM, et al. Resistance of HIV-1 to antiretroviral agents in
blood and seminal plasma: implications for transmission. AIDS. 1998;12:F181-189.
301 Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant
resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med.
1998;339:307-311.
302 Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals.
JAMA. 1999;282:1135-1141.
303 Paredes R, Clotet B. Clinical management of HIV-1 resistance. Antiviral Res.
2010;85:245-265.
304 Schrager LK, D’Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients
receiving potent antiretroviral combination therapy. JAMA. 1998;280:67-71.
305 Smith PD, Meng G, Salazar-Gonzalez JF, Shaw GM. Macrophage HIV-1 infection and
the gastrointestinal tract reservoir. J Leukoc Biol. 2003;74:642-649.
306 McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, Aldrovandi GM,
Cardoso SW, Santana JL, Brown TT. Bone disease in HIV infection: a practical review
and recommendations for HIV care providers. Clin Infect Dis. 2010;51(8):937-946.
307 Pyrgos V, Shoham S, Roilides E, Walsh TJ. Pneumocystis pneumonia in children.
Paediatr Resp Rev. 2009;10:192-198.
308 DeQuiros JCLB, Miro JM, Peña JM, et al. A randomized trial of the discontinuation of
primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly
active antiretroviral therapy in patients with HIV infection. N Engl J Med. 2001;344:159-
167.
309 Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality
among patients with advanced human immunodeficiency virus infection. N Engl J Med.
1998;338;853-860.
310 Szeto GL, Brice AK, Yang HC, Barber SA, Siliciano RF, Clements JE. Minocycline
attenuates HIV infection and reactivation by suppressing cellular activation in human
CD4+ T cells. J Infect Dis. 2010;201:1132-1140.
